Company intelligence / Profile preview
Pumis Biotechnology
Zhuhai, Guangdong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Pumis Biotechnology advanced clinical candidates like PM8002 (a bispecific antibody targeting PD-L1 and VEGF-A), now in Phase II for solid tumors, and PM1080 (an EGFR/cMet bispecific antibody) in Phase I, with promising safety and efficacy data presented at international oncology conferences. The company entered major licensing and acquisition deals in 2023–2024 with global pharma leaders, including BioNTech, reflecting an active and expanding clinical development pipeline.[1][2][7][9]
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodyAntibody-drug conjugateMonoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
BioNTechHanson Pharmaceuticals
Beyond the preview
Go deeper on Pumis Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pumis Biotechnology.